RxDoctor Payments DataLook up a doctor →

Noel Camba, MD

Cardiovascular Disease · Palos Park, ILNPI 1083668560

Payments from drug & device makers

$129,739in general payments, 2019–2025

Across 1,140 payments — averaging $113.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$69K
  • Esperion Therapeutics, Inc.$19K
  • Chiesi USA, Inc.$15K
  • Novartis$8K
  • AstraZeneca$8K
  • Medtronic$1K
  • plus $9K from 35 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$103,99680%
  • Travel & lodging$2,7552%
  • Food & beverage$22,11517%
  • Education$5720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,739 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$611,573
Medicare patients
2,379
Services billed
5,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban229$283,291
EntrestoSacubitril/Valsartan171$248,169
EliquisApixaban142$181,593
NexlizetBempedoic Acid/Ezetimibe41$40,470
Repatha SureclickEvolocumab46$34,577
VerquvoVericiguat21$28,878
FarxigaDapagliflozin Propanediol18$19,467
BrilintaTicagrelor16$11,985
Amiodarone Hcl132$6,647
Metoprolol Succinate347$5,236
Atorvastatin Calcium304$3,316
Diltiazem 24hr Er (Cd)Diltiazem Hcl118$3,148
Propranolol Hcl167$3,032
Clonidine26$2,847
Propranolol Hcl ErPropranolol Hcl46$2,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$69,013$283,291229 claims
NovartisEntresto$8,154$248,169171 claims
PfizerEliquis$879$181,593142 claims
Esperion Therapeutics, Inc.Nexlizet$19,248$40,47041 claims
AstraZenecaFarxiga, Brilinta$7,626$31,45334 claims
MerckVerquvo$767$28,87821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Palos Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →